Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lexaria Bioscience's EBIT per Share for the
three
months ended in May. 2026 was $-0.08.
Its EBIT per Share for the trailing twelve months (TTM) ended in May. 2026 was $-0.35.
During the past 3 years, the average EBIT per Share Growth Rate was 16.30% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 18.80% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 7.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Lexaria Bioscience's EBIT per Share or its related term are showing as below:
LEXX'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -372.3 Med: 9.7 Max: 84.6
Current: 16.3
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Lexaria Bioscience was 84.60% per year. The lowest was -372.30% per year. And the median was 9.70% per year.
LEXX's 3-Year EBIT Growth Rate is ranked better than 50.98% of 1171
companies
in the Biotechnology industry
Industry Median: 15.5
vs LEXX: 16.30
Lexaria Bioscience (NAS:LEXX) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Lexaria Bioscience EBIT per Share Related Terms
Lexaria Bioscience EBIT per Share Historical Data
* Premium members only.
The historical data trend for Lexaria Bioscience's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in May. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.35
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lexaria Bioscience (LEXX) has a EBIT per Share of $-0.35 as of May. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Lexaria Bioscience and its competitors. According to the industry distribution chart, Lexaria Bioscience ranks #574 out of 1171 companies in the Biotechnology industry, placing it in the top 49%.
Is Lexaria Bioscience's EBIT per Share too high?
Lexaria Bioscience's current EBIT per Share is $-0.35. Based on the distribution chart, Lexaria Bioscience ranks #574 out of 1171 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Lexaria Bioscience has a GF Score™ of 22/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lexaria Bioscience's EBIT per Share compare to CTXR and PTN?
According to the Biotechnology industry distribution chart, Lexaria Bioscience ranks #574 out of 1171 companies for EBIT per Share. This puts Lexaria Bioscience in the upper half of its industry. The industry median EBIT per Share is 15.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.50, based on 1,171 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Lexaria Bioscience and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lexaria Bioscience's current EBIT per Share is $-0.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lexaria Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Lexaria Bioscience (LEXX) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.37, compared to a current price of $0.54 — trading 46.9% above its estimated fair value. The current EBIT per Share is $-0.35. Lexaria Bioscience's overall GF Score™ is 22/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Lexaria Bioscience (LEXX), the current EBIT per Share is $-0.35 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lexaria Bioscience (LEXX) Overvalued in 2026?
Based on GuruFocus' analysis, Lexaria Bioscience stock appears to be overvalued.
The current stock price of $0.54 is trading 46.9% above its estimated GF Value™ of $0.37.
GuruFocus considers Lexaria Bioscience to be Significantly Overvalued.
Key valuation signals for LEXX:
EBIT per Share: $-0.35
GF Value™: $0.37 vs. price of $0.54 (46.9% above fair value)
No single metric tells the full story. See the LEXX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.
22GF Score
Get the complete analysis for LEXX
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LEXX has been successfully added to your 
